A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases

BACKGROUND: Immunotherapy targeting the PD-1 axis has activity in several tumor types. We aimed to determine the efficacy and safety of pembrolizumab in patients with untreated brain metastases. Here we present results from a Phase II trial of the PD-1 inhibitor pembrolizumab in patients with new or...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Oncol
Prif Awduron: Goldberg, Sarah B., Gettinger, Scott N., Mahajan, Amit, Chiang, Anne C., Herbst, Roy S., Sznol, Mario, Tsiouris, Apostolos John, Cohen, Justine, Vortmeyer, Alexander, Jilaveanu, Lucia, Yu, James, Hegde, Upendra, Speaker, Stephanie, Madura, Matthew, Ralabate, Amanda, Rivera, Angel, Rowen, Elin, Gerrish, Heather, Yao, Xiaopan, Chiang, Veronica, Kluger, Harriet M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5526047/
https://ncbi.nlm.nih.gov/pubmed/27267608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30053-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg